We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+55.52%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$7.04B
AUM Growth
+$1.98B
Cap. Flow
+$444M
Cap. Flow %
6.3%
Top 10 Hldgs %
74.64%
Holding
54
New
9
Increased
21
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$143M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$114M
3
PMVP icon
PMV Pharmaceuticals
PMVP
+$68.1M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$58.6M
5
ALT icon
Altimmune
ALT
+$40M

Top Sells

Rank Stock Value
1
ALLO icon
Allogene Therapeutics
ALLO
+$48.3M
2
ZGNX
Zogenix, Inc.
ZGNX
+$33.7M
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$27.1M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$25.3M
5
TCDA
Tricida, Inc. Common Stock
TCDA
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 66.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$2.23B 31.71%
26,250,000
– –
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$721M 10.25%
4,343,000
+56,235
+1% +$7.7M
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$594M 8.44%
7,650,000
+1,650,000
+28% +$114M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$2.07B
$314M 4.46%
9,536,039
-825,000
-8% -$25.3M
ASND icon
5
Ascendis Pharma A/S
ASND
$16.7B
$278M 3.95%
1,800,000
+50,000
+3% +$7.19M
MYOK
6
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$257M 3.65%
1,885,000
+5,000
+0.3% +$532K
ARGX icon
7
argenx
ARGX
$55.1B
$237M 3.37%
902,500
-67,500
-7% -$16.2M
SRPT icon
8
Sarepta Therapeutics
SRPT
$1.66B
$235M 3.34%
1,675,000
– –
ARNA
9
DELISTED
Arena Pharmaceuticals Inc
ARNA
$232M 3.29%
3,100,000
+2,150,000
+226% +$143M
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
$153M 2.18%
10,850,000
-150,000
-1% -$2.19M
XLRN
11
DELISTED
Acceleron Pharma
XLRN
$152M 2.16%
1,350,000
+310,000
+30% +$30.9M
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.9B
$133M 1.89%
1,750,000
-100,000
-5% -$10.1M
MRSN
13
DELISTED
Mersana Therapeutics
MRSN
$127M 1.8%
272,000
+12,000
+5% +$6.06M
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$12.5B
$106M 1.5%
890,000
+540,000
+154% +$58.6M
DCPH
15
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$93.4M 1.33%
1,820,000
-40,000
-2% -$1.96M
ADAP
16
DELISTED
Adaptimmune Therapeutics
ADAP
$87.8M 1.25%
11,000,000
+1,000,000
+10% +$8.75M
KPTI icon
17
Karyopharm Therapeutics
KPTI
$158M
$87.6M 1.24%
400,000
-66,667
-14% -$16.3M
CNST
18
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$86.6M 1.23%
4,275,000
+275,000
+7% +$6.71M
ADVM
19
DELISTED
Adverum Biotechnologies
ADVM
$82.4M 1.17%
800,000
+41,500
+5% +$6.21M
TRIL
20
DELISTED
Trillium Therapeutics Inc.
TRIL
$78.2M 1.11%
5,500,000
+750,000
+16% +$7.48M
KURA icon
21
Kura Oncology
KURA
$815M
$74.6M 1.06%
2,435,000
+1,385,000
+132% +$30.6M
CBAY
22
DELISTED
Cymabay Therapeutics
CBAY
$74.6M 1.06%
10,300,000
+5,050,000
+96% +$27M
QURE icon
23
uniQure
QURE
$2.78B
$64.5M 0.92%
1,750,000
+250,000
+17% +$10.2M
PMVP icon
24
PMV Pharmaceuticals
PMVP
$57.1M
$57.6M 0.82%
+1,850,000
New +$68.1M
RLMD icon
25
Relmada Therapeutics
RLMD
$546M
$56.4M 0.8%
1,500,000
+75,000
+5% +$2.9M
1
2 3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q3 2020 Portfolio in Review

As of Q3 2020, Avoro Capital Advisors held 54 positions worth $7.04B, up 39% from $5.06B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Avoro Capital Advisors deployed $444M of net new capital in Q3 2020, opening 9 new positions and adding to 21 existing holdings. Its largest new stake was PMV Pharmaceuticals: 1,850,000 shares worth $57.6M.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 80% a quarter earlier.

On the sell side, the largest reduction was Zogenix, Inc., an estimated $33.7M trimmed.

  • Avoro Capital Advisors's largest Q3 2020 buy was PMV Pharmaceuticals: 1,850,000 shares worth $57.6M.
  • Avoro Capital Advisors added most to Arena Pharmaceuticals Inc in Q3 2020, an estimated $143M increase.
  • Avoro Capital Advisors's biggest Q3 2020 reduction was Zogenix, Inc., cutting an estimated $33.7M.
  • Avoro Capital Advisors fully exited Allogene Therapeutics in Q3 2020, selling an estimated $48.3M.
  • Avoro Capital Advisors's ten largest holdings make up 75% of its $7.04B portfolio in Q3 2020.
  • Avoro Capital Advisors opened 9 new positions and closed 8 in Q3 2020.
  • Avoro Capital Advisors's portfolio value rose 39% quarter-over-quarter to $7.04B.

Based on Avoro Capital Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.